The clinicopathological and prognostic implications of tyrosine phosphatase SHP2 and ankyrin Hook1 gene expression in non- small cell lung cancer patients treated with gemcitabine plus platinum as first-line chemotherapy | Zendy

Hongyu Yang | Zendy; Lingjuan He | Zendy; Yi Zhang | Zendy; Yinyan Li | Zendy; Xin Huang | Zendy; Ying Li | Zendy; Yan Lou | Zendy; Lin-run Wang | Zendy

Open Access

The clinicopathological and prognostic implications of tyrosine phosphatase SHP2 and ankyrin Hook1 gene expression in non- small cell lung cancer patients treated with gemcitabine plus platinum as first-line chemotherapy

Author(s) -

Hongyu Yang,

Lingjuan He,

Yi Zhang,

Yinyan Li,

Xin Huang,

Ying Li,

Yan Lou,

Lin-run Wang

Publication year - 2020

Publication title -

annals of palliative medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.546

H-Index - 19

eISSN - 2224-5839

pISSN - 2224-5820

DOI - 10.21037/apm-20-430

Subject(s) - medicine , gemcitabine , chemotherapy , oncology , lung cancer , cancer research

SHP2, a widely expressed phosphatase, which has been linked to the initiation, progression and prognosis of various malignancies. We previously identified a new SHP2 anchorage protein Hook1 in the alveolar II epithelial cells, and it is suggested that Hook1 is a novel endogenous suppressor molecule of SHP2 phosphatase activity. Nevertheless, few studies have been mentioned the clinicopathological and prognostic relevance of SHP2 and Hook1 expression in patients with non-small cell lung cancer (NSCLC).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research